Role of exhaled nitric oxide in predicting steroid response in chronic obstructive pulmonary disease;A kilégzett nitrogén-monoxid szerepe a krónikus obstruktív tüdobetegség szteroidérzé kenységének meghatározásában

Orvosi Hetilap

Volumn 151, Issue 51, 2010, Pages 2083-2088

  Antus, Balázs ^a  

^a Orszagos Koranyi Tbc es Pulmonologiai Intezet   (Hungary)

Author keywords

airway infl ammation; COPD; exhaled nitric oxide; responsiveness; smoking; steroid

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; NITRIC OXIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG RESPONSE; EXHALATION; HUMAN; PREDICTION;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; BIOLOGICAL MARKERS; BREATH TESTS; BRONCHITIS; EOSINOPHILS; EXHALATION; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SMOKING;

EID: 78650366569     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2010.28972     Document Type: Article

References (50)

1. Bel, E. H.: Clinical phenotypes of asthma. Curr. Opin. Pulm. Med., 2004, 10, 44-50.
2. Bradding, P, Green, R. H.: Subclinical phenotypes of asthma. Curr. Opin. Allergy Clin. Immunol., 2010, 10, 54-59.
3. Wedzicha, J. A: The heterogeneity of chronic obstructive pulmonary disease. Thorax, 2000, 55, 631-632.
4. Celli, B. R.: Rogers Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance. Proc Am. Thorac Soc., 2006, 3, 461-465.
5. Böszörményi Nagy G.: Asztma és COPD: hasonlóságok és különbségek. Med. Thor., 2007, 60, 132-135.
6. Barnes, P. J., Adcock, I. M.: How do corticosteroids work in asthma? Ann. Intern. Med., 2003, 139, 359-370.
7. Barnes, P. J.: Corticosteroid resistance in airway disease. Proc Am. Thorac Soc., 2004, 1, 264-268.
8. Barnes, P. J., Ito, K., Adcock, I. M.: Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet, 2004, 363, 731-733.
9. Antus B., Horváth I.: Kilégzett nitrogén-monoxid a légúti betegségek diagnosztikájában és követésében. Orv. Hetil., 2007, 148, 1251-1257.
10. Antus B., Horváth I.: A nitrogén-monoxid szerepe a pulmonalis rendszerben. Med. Thor., 1996, 48, 162-166.
11. Horváth I.: A kilégzett nitrogén-monoxid- mérés szerepe az asthma bronchiale diagnózisában és kezelésében. Med. Thor., 2006, 59, 141-148.
12. Horváth I.: A kilégzett nitrogén-monoxid jelentsége asthma bronchialéban. LAM, 2005, 15, 265-272.
13. Czebe, K., Kullmann, T., Csiszer, E. és mtsai: Variability of exhaled breath condensate pH in lung transplant recipients. Respiration, 2008, 75, 322-327.
14. ATS/ERS Recommendations for Standardized Procedures for the Online and Offl ine Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005. Am. J. Respir. Crit. Care Med., 2005, 171, 912-930.
15. Silkoff, P. E., Carlson, M., Bourke, T. és mtsai: The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. J. Allergy Clin. Immunol., 2004, 114, 1241-1256.
16. Antus, B., Horvath, I., Barta, I.: Assessment of exhaled nitric oxide by a new hand-held device. Respir. Med., 2010, 104, 1377-1380.
17. Sandrini, A, Taylor, D. R., Thomas, P. S. és mtsai: Fractional exhaled nitric oxide in asthma: an update. Respirology, 2010, 15, 57-70.
18. Taylor, D. R., Pijnenburg, M. W., Smith, A. D. és mtsa: Exhaled nitric oxide measurements: clinical application and interpretation. Thorax, 2006, 61, 817-827.
19. Dummer, J. F., Taylor, D. R.: Defi ning the role of exhaled nitric oxide measurements in COPD. Respirology, 2010, 15, 385-386.
20. Antus, B., Csiszer, E., Czebe, K. és mtsa: Pulmonary infections increase exhaled nitric oxide in lung transplant recipients: a longitudinal study. Clin. Transplant., 2005, 19, 377-382.
21. www.ginasthma.com (accessed on October 27, 2010).
22. Antus, B., Barta, I., Czebe, K. és mtsai: Analysis of cytokine pattern in exhaled breath condensate of lung transplant recipients with bronchiolitis obliterans syndrome. Infl amm. Res., 2010, 59, 83-86.
23. Kharitonov, S. A, Robbins, R. A, Yates, D. és mtsai: Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am. J. Respir. Crit. Care Med., 1995, 152, 609-612.
24. Orosz M., Tamási L., Gálffy G.: A dohányzás és asztma-kontroll vizsgálata hazai betegekben. Med. Thor., 2009, 62, 112-119.
25. Schafroth Török, S., Leuppi, J. D.: Bronchial hyper-responsiveness and exhaled nitric oxide in chronic obstructive pulmonary disease. Swiss. Med. Wkly, 2007, 137, 385-391.
26. Little, S. A, Chalmers, G. W, MacLeod, K. J. és mtsai: Non-invasive markers of airway infl ammation as predictors of oral steroid responsiveness in asthma. Thorax, 2000, 55, 232-234.
27. Smith, A. D., Cowan, J. O., Brassett, K. P. és mtsai: Exhaled nitric oxide: a predictor of steroid response. Am. J. Respir. Crit. Care Med., 2005, 172, 453-459
28. Szefler, S. J., Phillips, B. R., Martinez, F. D. és mtsai: Characterization of within-subject responses to fl uticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol., 2005, 115, 233-242.
29. Cowan, D. C, Cowan, J. O., Palmay, R. és mtsai: Effects of steroid therapy on infl ammatory cell subtypes in asthma. Thorax, 2010, 65, 384-390.
30. Montuschi, P, Kharitonov, S. A, Barnes, P. J.: Exhaled carbon monoxide and nitric oxide in COPD. Chest, 2001, 120, 496-501.
31. Corradi, M., Majori, M., Cacciani, G. C. és mtsai: Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease. Thorax, 1999, 54, 572-575.
32. Rutgers, S. R., Meijer, R. J., Kerstjens, H. A. és mtsai: Nitric oxide measured with single-breath and tidal-breathing methods in asthma and COPD. Eur. Respir. J., 1998, 12, 816-819.
33. Delen, F. M., Sippel, J. M., Osborne, M. L. és mtsai: Increased exhaled nitric oxide in chronic bronchitis: comparison with asthma and COPD. Chest, 2000, 117, 695-701.
34. Narang, I., Ersu, R., Wilson, N. M. és mtsa: Nitric oxide in chronic airway infl ammation in children: diagnostic use and pathophysiological signifi cance. Thorax, 2002, 57, 586-589.
35. Bhowmik, A, Seemungal, T. A., Donaldson, G C. és mtsa: Effects of exacerbations and seasonality on exhaled nitric oxide in COPD.Eur. Respir. J., 2005, 26, 1009-1015.
36. Clini, E., Bianchi, L., Pagani, M. és mtsa: Endogenous nitric oxide in patients with stable COPD: correlates with severity of disease. Thorax, 1998, 53, 881-883.
37. Maziak, W., Loukides, S., Culpitt, S. és mtsai: Exhaled nitric oxide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 1998, 157, 998-1002.
38. Ferreira, I. M., Hazari, M. S., Gutierrez, C. és mtsai: Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effects of inhaled beclomethasone. Am. J. Respir. Crit. Care Med., 2001, 164, 1012-1025.
39. Zietkowski, Z., Kucharewicz, I., Bodzenta-Lukaszyk, A.: The infl uence of inhaled corticosteroids on exhaled nitric oxide in stable chronic obstructive pulmonary disease. Respir. Med., 2005, 99, 816-824.
40. Pizzichini, E., Pizzichini, M. M., Gibson, P. és mtsai: Sputum eosinophilia predicts benefi t from prednisone in smokers with chronic obstructive bronchitis. Am. J. Respir. Crit. Care Med., 1998, 158, 1511-1517.
41. Fujimoto, K., Kubo, K., Yamamoto, H. és mtsai: Eosinophilic infl ammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. Chest, 1999, 115, 697-702.
42. Brightling, C. E., Monteiro, W, Ward, R. és mtsai: Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 2000, 356, 1480-1485.
43. Leigh, R., Pizzichini, M. M., Morris, M. M. és mtsai: Stable COPD: predicting benefi t from high-dose inhaled corticosteroid treatment. Eur. Respir. J., 2006, 27, 964-971.
44. Papi, A., Romagnoli, M., Baraldo, S. és mtsai: Partial reversibility of airfl ow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2000, 162, 1773-1777.
45. Kunisaki, K. M., Rice, K. L., Janoff, E. N. és mtsai: Exhaled nitric oxide, systemic infl ammation, and the spirometric response to inhaled fl uticasone propionate in severe chronic obstructive pul-monary disease: a prospective study Ther. Adv. Respir. Dis., 2008, 2, 55-64.
46. Dummer, J. F., Epton, M. J., Cowan, J. O. és mtsai: Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am. J. Respir. Crit. Care Med., 2009, 180, 846-852.
47. Agusti, A. G., Villaverde, J. M., Togores, B. és mtsai: Serial mea-surements of exhaled nitric oxide during exacerbations of chron-ic obstructive pulmonary disease. Eur. Respir. J., 1999, 14, 523-528.
48. Antus, B., Barta, I., Kullmann, T. és mtsai: Assessment of ex-haled breath condensate pH in exacerbation of asthma and COPD: a longitudinal study Am. J. Respir. Crit. Care Med., 2010 Jul 23. [Epub ahead of print] (In press.)
49. Antus, B., Barta, I., Horvath, I. és mtsa: Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbation. Respirology, 2010, 15, 472-477.
50. www.goldcopd.com (accessed on October 27, 2010).